DORADO, PUERTO RICO--(Marketwire - Feb 25, 2013) - Pharma-Bio Serv Inc., ("Pharma-Bio Serv" or the "Company"), (OTCQB: PBSV), a global compliance and validation services consulting solutions provider, today announced it has engaged CorProminence LLC, a leading investor relations and strategic advisory firm, to assist in the Company's shareholder communication efforts. CorProminence will assist the Company in expanding market awareness and conveying the Company's key messages to the investment community. CorProminence LLC, a boutique investor relations firm, specializes in integrated corporate communications strategies for small-cap companies.
"We are pleased to announce the engagement of CorProminence and look forward to working with them," said Nélida Plaza, Acting President and CEO of Pharma-Bio Serv and President of Puerto Rico Operations.
Scott Gordon, President of CorProminence commented, "CorProminence is well suited to assist Pharma-Bio Serv, and effectively communicate their business and growth strategy to raise awareness of the Company within the investment community. We look forward to working with the team at Pharma-Bio Serv to help achieve their goals."
About Pharma-Bio Serv Inc.
Pharma-Bio Serv is a global compliance and validation services consulting solutions provider, headquartered in Puerto Rico, with operations in the U.S., Ireland and Spain. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance related services with integrated portfolio services including microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at our laboratory testing facility in Puerto Rico. Our services also include "Integratek," our Microsoft Certified Partner information technology consulting practice and the "Pharma Serv Academy" of training centers that provide state-of-the-art technical and regulatory standards seminars/training through conducted by our network of leading industry experts in their fields, which include both in-house and sourced resources. Our global team includes more than 275 leading engineering and life science professionals, quality assurance managers and directors.
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this news release. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this news release, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2012 and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.